Leap Therapeutics, Inc.

Informe acción NasdaqCM:LPTX

Capitalización de mercado: US$93.0m

Leap Therapeutics Dirección

Dirección controles de criterios 3/4

El CEO de Leap Therapeutics' es Doug Onsi , nombrado en Jan 2011, tiene una permanencia de 13.25 años. compensación anual total es $1.88M, compuesta por 33.8% salario y 66.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.29% de las acciones de la empresa, por valor de $236.40K. La antigüedad media del equipo directivo y de la junta directiva es de 4 años y 7.3 años, respectivamente.

Información clave

Doug Onsi

Chief Executive Officer (CEO)

US$1.5m

Compensación total

Porcentaje del salario del CEO43.6%
Permanencia del CEO13.4yrs
Participación del CEO0.2%
Permanencia media de la dirección4.2yrs
Promedio de permanencia en la Junta Directiva7.4yrs

Actualizaciones recientes de la dirección

Recent updates

Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Deliver On Growth Plans?

Mar 13
Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Deliver On Growth Plans?

Will Leap Therapeutics (NASDAQ:LPTX) Spend Its Cash Wisely?

Nov 22
Will Leap Therapeutics (NASDAQ:LPTX) Spend Its Cash Wisely?

Leap Therapeutics GAAP EPS of -$0.15 misses by $0.05

Aug 12

Leap Therapeutics begins trials of DKN-01 in gastric/colorectal cancers

Jul 12

Leap Therapeutics: 2 Catalysts With Cancer Drug DKN-01 In The 2nd Half Of 2022

Jun 27

Here's Why We're Watching Leap Therapeutics' (NASDAQ:LPTX) Cash Burn Situation

May 01
Here's Why We're Watching Leap Therapeutics' (NASDAQ:LPTX) Cash Burn Situation

Leap Therapeutics: Waiting For One More Leap

Feb 18

We're Hopeful That Leap Therapeutics (NASDAQ:LPTX) Will Use Its Cash Wisely

Jan 04
We're Hopeful That Leap Therapeutics (NASDAQ:LPTX) Will Use Its Cash Wisely

Leap Therapeutics: What Prompted Prioritizing This Precision Oncology Company?

Nov 29

Leap Therapeutics: All On The Line

Oct 13

Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Invest In Growth?

Sep 15
Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Invest In Growth?

Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Invest In Growth?

Jun 01
Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Invest In Growth?

Companies Like Leap Therapeutics (NASDAQ:LPTX) Are In A Position To Invest In Growth

Mar 03
Companies Like Leap Therapeutics (NASDAQ:LPTX) Are In A Position To Invest In Growth

Could The Leap Therapeutics, Inc. (NASDAQ:LPTX) Ownership Structure Tell Us Something Useful?

Jan 27
Could The Leap Therapeutics, Inc. (NASDAQ:LPTX) Ownership Structure Tell Us Something Useful?

Announcing: Leap Therapeutics (NASDAQ:LPTX) Stock Increased An Energizing 127% In The Last Year

Dec 23
Announcing: Leap Therapeutics (NASDAQ:LPTX) Stock Increased An Energizing 127% In The Last Year

Need To Know: Analysts Are Much More Bullish On Leap Therapeutics, Inc. (NASDAQ:LPTX)

Nov 18
Need To Know: Analysts Are Much More Bullish On Leap Therapeutics, Inc. (NASDAQ:LPTX)

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Doug Onsi en comparación con los beneficios de Leap Therapeutics?
FechaCompensación totalSalarioIngresos de la empresa
Mar 31 2024n/an/a

-US$53m

Dec 31 2023US$2mUS$669k

-US$81m

Sep 30 2023n/an/a

-US$81m

Jun 30 2023n/an/a

-US$82m

Mar 31 2023n/an/a

-US$86m

Dec 31 2022US$2mUS$637k

-US$55m

Sep 30 2022n/an/a

-US$53m

Jun 30 2022n/an/a

-US$49m

Mar 31 2022n/an/a

-US$42m

Dec 31 2021US$2mUS$596k

-US$41m

Sep 30 2021n/an/a

-US$37m

Jun 30 2021n/an/a

-US$32m

Mar 31 2021n/an/a

-US$29m

Dec 31 2020US$2mUS$513k

-US$38m

Sep 30 2020n/an/a

-US$39m

Jun 30 2020n/an/a

-US$40m

Mar 31 2020n/an/a

-US$42m

Dec 31 2019US$817kUS$400k

-US$33m

Sep 30 2019n/an/a

-US$24m

Jun 30 2019n/an/a

-US$22m

Mar 31 2019n/an/a

-US$21m

Dec 31 2018US$682kUS$400k

-US$23m

Sep 30 2018n/an/a

-US$31m

Jun 30 2018n/an/a

-US$31m

Mar 31 2018n/an/a

-US$31m

Dec 31 2017US$3mUS$397k

-US$30m

Compensación vs. Mercado: La compensación total de Doug($USD1.88M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD677.87K).

Compensación vs. Ingresos: La compensación de Doug ha sido consistente con los resultados de la empresa en el último año.


CEO

Doug Onsi (55 yo)

13.4yrs

Permanencia

US$1,534,507

Compensación

Mr. Douglas E. Onsi, also known as Doug, J.D., serves as Director at Leap Therapeutics, Inc. since March 18, 2020. He serves as Managing Director of HCV Management VIII, LLC (formerly known as HealthCare V...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Douglas Onsi
CFO, General Counsel13.4yrsUS$1.53m0.19%
$ 179.0k
Augustine Lawlor
Chief Operating Officer8.4yrsUS$1.00m0.013%
$ 12.4k
Cynthia Sirard
Chief Medical Officer4.2yrsUS$999.40k0.013%
$ 12.2k
Jason Baum
Chief Scientific Officer1.2yrssin datossin datos
Mark O'Mahony
Chief Manufacturing Officer4.2yrssin datos0.013%
$ 12.2k
Christine Granfield
VP and Head of Regulatory Affairs & Quality3.8yrssin datossin datos

4.2yrs

Permanencia media

54.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de LPTX se considera experimentado (4 años antigüedad media).


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Douglas Onsi
CFO, General Counsel4.3yrsUS$1.53m0.19%
$ 179.0k
Christopher Mirabelli
Chairman13.4yrsUS$744.18k0.013%
$ 12.4k
James Cavanaugh
Independent Director8.4yrsUS$126.62k0%
$ 0
Thomas Dietz
Lead Independent Director8.4yrsUS$188.86k0%
$ 0
Nissim Mashiach
Independent Director7.4yrsUS$118.24k0%
$ 0
Joseph Loscalzo
Independent Director8.4yrsUS$112.12k0%
$ 0
William Li
Independent Director7.4yrsUS$121.62k0%
$ 0
Carl Nathan
Member of Scientific Advisory Boardno datasin datossin datos
Richard Schilsky
Independent Director1.8yrsUS$112.12k0%
$ 0
Richard Brian Gaynor
Member of Scientific Advisory Board3.4yrssin datossin datos
David Tuveson
Member of Scientific Advisory Boardno datasin datossin datos
Andrew Nixon
Member of Scientific Advisory Board3.4yrssin datossin datos

7.4yrs

Permanencia media

70yo

Promedio de edad

Junta con experiencia: La junta directiva de LPTX se considera experimentada (7.3 años de antigüedad promedio).